Association between metabolic disease and cardiovascular risk in patients with schizophrenia treated with antipsychotics

被引：0
|
作者：
Vataire, A. [1 ]
Ferchichi, S. [1 ]
Desroziers, K. [1 ]
Cadi-Soussi, N. [2 ]
Murthy, V. [3 ]
Toumi, M. [4 ]
机构：
[1] Creativ Ceut, Paris, France
[2] Takeda Pharmaceut Int GmbH, Zurich, Switzerland
[3] Takeda Dev Ctr Europe, London, England
[4] Univ Lyon 1, F-69365 Lyon, France
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2013年 / 23卷
关键词：
D O I：
10.1016/S0924-977X(13)70785-5
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.f.007
引用
收藏
页码：S495 / S495
页数：1
相关论文
共 50 条
  • [41] The Genetic Association of FTO Variants With Metabolic Traits in Patients With Schizophrenia May Be Modified by Antipsychotics
    Huang, Ming-Chyi
    Kao, Chung-Feng
    Chiu, Chih-Chiang
    Kuo, Po-Hsiu
    Chen, Po-Yu
    Lu, Mong-Liang
    Chen, Chun-Hsin
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (01) : 162 - 165
  • [42] Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, Schizoaffective disorder, and bipolar disorder
    Kilbourne, Amy M.
    Brar, Jaspreet S.
    Drayer, Rebecca A.
    Xu, Xiangyan
    Post, Edward P.
    PSYCHOSOMATICS, 2007, 48 (05) : 412 - 417
  • [43] Association of Metabolic Syndrome and Hyperferritinemia in Patients at Cardiovascular Risk
    Tofano, Ricardo Jose
    Pescinni-Salzedas, Leticia Maria
    Baisi Chagas, Eduardo Federighi
    Penteado Detregiachi, Claudia Rucco
    Guiguer, Elen Landgraf
    Araujo, Adriano Cressoni
    Bechara, Marcelo Dib
    Rubira, Claudio Jose
    Barbalho, Sandra Maria
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2020, 13 : 3239 - 3248
  • [44] Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: Results from the CLAMORS study
    Bobes, J.
    Arango, C.
    Aranda, P.
    Carmena, R.
    Garcia-Garcia, M.
    Rejas, J.
    EUROPEAN PSYCHIATRY, 2012, 27 (04) : 267 - 274
  • [45] Interventions in antipsychotics-treated patients with cardiometabolic risk factors or metabolic syndrome
    Larsen, J.
    Holdrup, M.
    Christensen, B.
    Sigalin, C.
    Nilsson, P. M.
    Kolb, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S440 - S441
  • [46] Association between glucose-dependent insulinotropic polypeptide receptor gene and lipid profiles in schizophrenia patients treated with antipsychotics
    Fukui, N.
    Suzuki, Y.
    Ono, S.
    Sugai, T.
    Watanabe, J.
    Tsuneyama, N.
    Saito, M.
    Tajiri, M.
    Someya, T.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S544 - S544
  • [47] Association between psychiatric hospitalizations of patients with schizophrenia and polygenic risk scores based on genes with altered expression by antipsychotics
    Facal, Fernando
    Arrojo, Manuel
    Paz, Eduardo
    Paramo, Mario
    Costas, Javier
    ACTA PSYCHIATRICA SCANDINAVICA, 2022, 146 (02) : 139 - 150
  • [48] ASSOCIATION IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA BETWEEN WITHDRAWAL PSYCHOSIS AND ANTIPSYCHOTICS
    Kimura, H.
    Kanahara, N.
    Komatsu, N.
    Ishige, M.
    Muneoka, K.
    Suzuki, T.
    Yamanaka, H.
    Yoshimura, M.
    Komatsu, H.
    Watanabe, H.
    Iyo, M.
    EUROPEAN PSYCHIATRY, 2014, 29
  • [49] Metabolic syndrome in schizophrenic patients treated with antipsychotics
    Peuskens, J
    De Hert, M
    Van Eyck, D
    Wampers, M
    de Patoul, A
    Hanssens, L
    Scheen, A
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 568 - 568
  • [50] Age specific prevalence of metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics and control group
    Ahmadkhaniha, Hamidreza
    Mostafavi, Hamid Abdolmaleki
    Nojoomi, Marzieh
    Parvizi-Emran, Bahman
    HEALTHMED, 2012, 6 (11): : 3680 - 3684
12345